Y. Furuta

发表

Maporal Virus as a Surrogate for Pathogenic New World Hantaviruses and its Inhibition by Favipiravir

D. Smee, B. Gowen, Kristin K Buys, 2011, Antiviral chemistry & chemotherapy.

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Y. Furuta, Takaaki Nakamura, T. Komeno, 2017, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase

N. Nomura, Y. Furuta, H. Nishikawa, 2013, Antimicrobial Agents and Chemotherapy.

In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705

H. Narita, N. Nomura, K. Takahashi, 2002, Antimicrobial Agents and Chemotherapy.

Antiviral Efficacy of Favipiravir against Two Prominent Etiological Agents of Hantavirus Pulmonary Syndrome

H. Feldmann, D. Falzarano, D. Safronetz, 2013, Antimicrobial Agents and Chemotherapy.

In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections

M. Mendenhall, R. Sidwell, B. Gowen, 2007, Antimicrobial Agents and Chemotherapy.

Maporal Hantavirus ββ-Integrin Utilization and Sensitivity to Favipiravir

B. Gowen, Kristin K Buys, Y. Furuta, 2010 .

Hepatitis B virus carriers without precore mutations in hepatitis B e antigen‐negative stage show more severe liver damage

A. Dhillon, G. Norkrans, M. Lindh, 1996, Hepatology.

Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.

C. Czerkinsky, J. Holmgren, B. Svennerholm, 1994, Proceedings of the National Academy of Sciences of the United States of America.

In Vitro and in Vivo Activities of T-705 and Oseltamivir against Influenza Virus

N. Nomura, M. Kuno, Y. Furuta, 2003, Antiviral chemistry & chemotherapy.

Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever

D. Smee, M. Mendenhall, B. Gowen, 2011, PLoS neglected tropical diseases.

Favipiravir (T-705) protects against Nipah virus infection in the hamster model

Benhur Lee, Alexander N. Freiberg, Jennifer K. Smith, 2018, Scientific Reports.

Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients

B. Gowen, Brady T. Hickerson, J. Westover, 2018, The Journal of infectious diseases.

Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice

T. Steiner, B. Gowen, Brady T. Hickerson, 2019, Pathogens.

Heartland virus infection in hamsters deficient in type I interferon signaling: Protracted disease course ameliorated by favipiravir.

S. Thangamani, B. Gowen, Brady T. Hickerson, 2017, Virology.

Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice.

D. Smee, D. Barnard, E. B. Tarbet, 2013, Future virology.

Favipiravir (T-705) Inhibits Junín Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever

B. Gowen, E. Sefing, Alexander N. Freiberg, 2013, PLoS neglected tropical diseases.

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections

D. Smee, D. Barnard, B. Gowen, 2009, Antiviral Research.

In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.

M. Mendenhall, R. Sidwell, B. Gowen, 2007, Antimicrobial agents and chemotherapy.

Favipiravir (T‐705) but not ribavirin is effective against two distinct strains of Crimean‐Congo hemorrhagic fever virus in mice

H. Feldmann, K. Rosenke, David W. Hawman, 2018, Antiviral research.

Efﬁcacy of Orally Administered T-705 on Lethal Avian Inﬂuenza A (H5N1) Virus Infections in Mice (cid:1)

D. Smee, D. Barnard, R. Sidwell, 2007 .

Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.

D. Smee, M. Bray, B. Gowen, 2016, Antiviral research.

T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture

D. Smee, J. Nunberg, J. C. de la Torre, 2010, Antimicrobial Agents and Chemotherapy.

Susceptibility of Type I Interferon Receptor Knock-Out Mice to Heartland Bandavirus (HRTV) Infection and Efficacy of Favipiravir and Ribavirin in the Treatment of the Mice Infected with HRTV

M. Shimojima, S. Fukushi, M. Saijo, 2022, Viruses.

No significant enhancement of protection by Tat‐expressing Sendai viral vector‐booster in a macaque AIDS model

Y. Nagai, T. Shioda, T. Matano, 2003, AIDS.

Favipiravir treatment prolongs the survival in a lethal mouse model intracerebrally inoculated with Jamestown Canyon virus

S. Fukushi, M. Saijo, T. Yoshikawa, 2021, PLoS neglected tropical diseases.

Developmental expression of two CXC chemokines, MIP-2 and KC, and their receptors.

A. Richmond, J. Luan, J. Du, 2001, Cytokine.

Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models.

D. Smee, B. Gowen, M. Wong, 2010, Antiviral research.

Use of Favipiravir to Treat Lassa Virus Infection in Macaques

H. Feldmann, K. Rosenke, D. Safronetz, 2018, Emerging infectious diseases.

Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.

D. Smee, B. Gowen, J. Westover, 2015, Antiviral research.

Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.

B. Gowen, J. Westover, K. Bailey, 2014, Antiviral research.

Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.

D. Smee, E. B. Tarbet, Y. Babu, 2012, Antiviral research.

Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells.

D. Smee, B. Hurst, Y. Furuta, 2009, The Journal of antimicrobial chemotherapy.

Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy.

B. Gowen, J. Westover, E. Sefing, 2017, Antiviral research.

The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset

H. Feldmann, K. Rosenke, D. Safronetz, 2015, Scientific Reports.

Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration

M. Shimojima, S. Fukushi, M. Saijo, 2018, bioRxiv.

Effects of Combinations of Favipiravir ( T-705 ) and Oseltamivir on Influenza A ( H 1 N 1 , H 3 N 2 , and H 5 N 1 ) Virus Infections in Mice

D. Smee, K. Bailey, B. Hurst, 2017 .

Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Inﬂuenza A Virus Infections in Mice (cid:1) †

D. Smee, K. Bailey, B. Hurst, 2009 .

Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir

B. Gowen, Brady T. Hickerson, J. Westover, 2016, Journal of Virology.

A cell-based screening system for influenza A viral RNA transcription/replication inhibitors

M. Kiso, H. Goto, Shinji Watanabe, 2013, Scientific Reports.

M Segment-Based Minigenome System of Severe Fever with Thrombocytopenia Syndrome Virus as a Tool for Antiviral Drug Screening

M. Shimojima, M. Saijo, Y. Matsuura, 2021, Viruses.

Favipiravir (T-705), a novel viral RNA polymerase inhibitor.

D. Smee, D. Barnard, B. Gowen, 2013, Antiviral research.

Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques.

H. Feldmann, David W. Hawman, B. Gowen, 2020, Antiviral research.

HIV type 1 V3 sequence diversity in contact-traced Swedish couples at the time of sexual transmission.

G. Norkrans, T. Bergström, Y. Furuta, 1994, AIDS research and human retroviruses.

Emergence of precore TAG mutation during hepatitis B e seroconversion and its dependence on pregenomic base pairing between nucleotides 1858 of 1896.

G. Norkrans, A. Vahlne, M. Lindh, 1995, The Journal of infectious diseases.

Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis

A. Nishizono, Y. Furuta, T. Komeno, 2015, The Journal of infectious diseases.

Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection

R. Sidwell, J. Julander, Y. Furuta, 2007, Antimicrobial Agents and Chemotherapy.

In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses

Hideo Goto, Hiroshi Mitamura, Gabriele Neumann, 2009, Nature.

The Twenty-Third International Conference on Antiviral Research

X. Chen, Y. Pommier, D. Smee, 2010, Antiviral Research.

[In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].

H. Yamada, Hisashi Yamada, N. Nomura, 2002, The Japanese journal of antibiotics.

Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis.

H. Tani, Y. Morinaga, Y. Furuta, 2022, Antiviral research.

Effect of T-705 treatment on western equine encephalitis in a mouse model.

D. Smee, J. Morrey, J. Julander, 2009, Antiviral research.

Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents.

Hong Wang, D. Smee, V. Siddharthan, 2008, Antiviral research.

Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106

D. Smee, J. Morrey, J. Julander, 2008, Antimicrobial Agents and Chemotherapy.

Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice

D. Smee, D. Barnard, R. Sidwell, 2006, Antimicrobial Agents and Chemotherapy.

Mechanism of Action of T-705 against Influenza Virus

Nobuhiko Nomura, N. Nomura, Kazumi Takahashi, 2005, Antimicrobial Agents and Chemotherapy.

Detection of hepatitis B virus precore TAG mutant by an amplification-created restriction site method.

G. Norkrans, M. Lindh, Y. Furuta, 1995, The Journal of infectious diseases.

Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis.

A. Nishizono, Y. Furuta, T. Komeno, 2019, Antiviral research.

In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus

D. Smee, D. Barnard, A. Vollmer, 2014, Archives of Virology.

Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice

D. Smee, K. Bailey, B. Hurst, 2009, Antimicrobial Agents and Chemotherapy.

Treatment of Late Stage Disease in a Model of Arenaviral Hemorrhagic Fever: T-705 Efficacy and Reduced Toxicity Suggests an Alternative to Ribavirin

D. Smee, J. Stevens, B. Gowen, 2008, PloS one.

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

Yoshihiro Kawaoka, Makoto Ozawa, M. Kiso, 2009, Proceedings of the National Academy of Sciences.

Effects of Differentiation-Inducing Factor-1 (DIF-1) of Dictyostelium discoideum on Bacteria, Fungi, and an Influenza Virus

Y. Kubohara, M. Kuno, Y. Furuta, 2002 .

T-705 Treatment of Late Stage Disease in an Arenaviral Hemorrhagic Fever Model:T-705 Efficacy and Reduced Toxicity Suggests a Viable Alternative to RibavirinTherapy

D. Smee, J. Stevens, B. Gowen, 2008 .

Administration of the antiviral agent T-1105 fully protects pigs from foot-and-mouth disease infection.

Tatsuya Nishi, K. Morioka, Rie Kawaguchi, 2022, Antiviral research.

Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses

Ryo Takano, M. Kiso, M. Yamashita, 2010, PLoS pathogens.

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.

G. Neumann, Y. Kawaoka, M. Tashiro, 2016, Antiviral research.

In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses

Vasiliy P. Mishin, Katrina Sleeman, Larisa V. Gubareva, 2010, Antimicrobial Agents and Chemotherapy.

Evaluation of a novel severe combined immunodeficiency mouse model for antiviral drug evaluation against Chandipura virus infection.

H. Ebihara, M. Saijo, Tadaki Suzuki, 2023, Antiviral research.

Strain-dependent disease and response to favipiravir treatment in mice infected with Chikungunya virus.

D. Smee, J. Julander, Y. Furuta, 2020, Antiviral research.

Favipiravir (T-705) protects against Nipah virus infection in the hamster model

Benhur Lee, Alexander N. Freiberg, Jennifer K. Smith, 2018, Scientific Reports.

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections

D. Smee, D. Barnard, B. Gowen, 2009, Antiviral Research.

The inhibition of FMD virus excretion from the infected pigs by an antiviral agent , T-1105

R. Yamazoe, Y. Furuta, K. Sakamoto, 2007 .